SecBot SecBot
DEFM14A ·Filed Sep 4, 2026

BLFS

BIOLIFE SOLUTIONS INC
BULLISH
Impact 7/10
Horizonweeks Processed2mo ago SEC0001193125-26-383837
Notable filing: DEFM14A
Actionable Insight ▲ Bullish

BioLife shareholders should vote FOR the merger proposal at the special meeting on October 5, 2026. If approved, the merger is expected to close in Q4 2026, and shares should trade near the implied merger consideration value until closing. Monitor for any competing proposals or regulatory delays.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$35.38
T+0 close · Sep 4, 2026 · via day close
Latest settled
+9.13%
T+20 · $38.61
Vs SPY
+7.42%
α at T+20
Next horizon
T+60
in 15d
  1. T+0 · Sep 8 $35.38entry
  2. T+1 · 2mo ago −1.27%α −0.81% · $34.93
  3. T+5 · 2mo ago +2.85%α +3.97% · $36.39
  4. T+20 · 6w ago +9.13%α +7.42% · $38.61
  5. T+49 · todayOpen
  6. T+60 · in 15d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioLife Solutions (BLFS) is seeking stockholder approval for its acquisition by Repligen Corporation (RGEN) in a cash-and-stock deal offering $11.25 cash plus 0.1442 RGEN shares per BLFS share. The BioLife board unanimously recommends voting FOR, with the special meeting scheduled for October 5, 2026. If approved, the merger is expected to close in Q4 2026, and BLFS stockholders will own approximately 11.1% of the combined company.

Key Financial Metrics

Deal Type
merger

Key Facts

  • Merger consideration: $11.25 cash + 0.1442 shares of Repligen common stock per BioLife share
  • Implied value per BioLife share: $31.00 as of July 21, 2026 (pre-announcement) and $36.19 as of September 2, 2026
  • BioLife stockholders will own approximately 11.1% of Repligen post-merger
  • Special meeting: October 5, 2026; vote requires majority of outstanding shares
  • Board unanimously recommends FOR (with Tony Hunt recused)
  • Centerview Partners fairness opinion: consideration fair from a financial point of view
  • Termination fee of $59 million payable by BioLife in certain circumstances
  • Appraisal rights available under Delaware law
  • Expected closing: Q4 2026, subject to stockholder approval, HSR clearance, and other conditions

Financial Impact

Per share consideration of $11.25 cash plus 0.1442 shares of Repligen common stock, implying a value of approximately $36.19 per BioLife share as of September 2, 2026.

share priceownership structure

Risk Factors

  • Failure to obtain stockholder approval (requires majority of outstanding shares)
  • Regulatory hurdles including HSR and foreign investment approvals
  • Termination fee of $59 million if deal falls through under certain conditions
  • Potential for appraisal rights litigation

Market Snapshot

Exchange
Nasdaq
Sector
Electromedical & Electrotherapeutic Apparatus
Analyst Consensus
47% bullish (15 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

DocumentAccession Number
DEFM14A Filing (Primary)0001193125-26-383837
Document: d112843ddefm14a.htm0001193125-26-383837

Track record

15 reports on BLFS

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry price pending
  2. Nov 6, 202610d ago Institutional Cluster Bearish 4/10 No price data
  3. Oct 27, 202620d ago SC 13G/A Neutral 3/10 No price data
  4. Oct 16, 20264w ago 15-12G Neutral 4/10 No price data
  5. Oct 13, 20264w ago EFFECT Neutral 3/10 No price data
  6. Oct 13, 20264w ago EFFECT Neutral 3/10 No price data
  7. Oct 6, 20265w ago 8-K Bullish 7/10 Entry $39.00 No price data
  8. Sep 30, 20266w ago 425 Neutral 4/10 Entry $38.85 No price data
  9. Sep 30, 20266w ago DEFA14A Neutral 4/10 Entry $38.85 No price data
  10. Sep 24, 20267w ago SC 13G Neutral 4/10 Entry $38.58 No price data
Showing 10 of 15

US Market Status

Market Closed · Opens Wed (11h 41m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 4, 2026